![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, September 25, 2022 1:39:39 PM
The higher move spiked quickly, and didn’t last long at all, however these moves establish that the share price can easily go up quickly on solidly good news and press, such as approvals news.
So imo I believe the sp could quickly get to $3-$5 or more on such news, making a buyout at around $10+ supportable, except many of us longs think nwbo wants at least $20 per share in a buyout.
It’s been a long journey for early investors, and the recent investors are in a great position of still being able to buy shares less than 75 cents, many of the earlier concerns being derisked, such as the phase 3 trial completed and met endpoints of mOS, manufacturing certified, and approvals reasonably within sight!
The natural reaction is how can an investment in this status still be at less than $1B market cap?
Dig in and analyse all the available due diligence and consider the reputations and quality of the neurosurgeons and medical centers involved in the large multinational trial, and draw your own conclusions and odds of success.
I constantly torture myself over every breadcrumb of due diligence and run through the logic, and still/always come out thinking the risk-reward is very favorable imo.
I’ve invested more than I would have ever thought to invest into a sub dollar stock and try hard not to further invest large additional funds on the principle that I must not risk my family’s standard of living no matter how good the odds look.
Besides, I accumulated (and still accumulate small numbers of additional) shares enough to improve our finances significantly at $5-$10, and generational wealth at $20+ !!!
You do you
![smile](/images/emoticon01.gif)
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM